From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma

Endocrine Pathology

Volumn 23, Issue 1, 2012, Pages 15-20

  Cascón, Alberto ^a,b   Tennant, Daniel A ^c  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

MAX; Mutation detection; Paraganglioma; Pheochromocytoma; Pseudohypoxia; Transcriptional regulation

Indexed keywords

CARCINOGENESIS; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC TRANSCRIPTION; INHERITANCE; NUCLEOTIDE SEQUENCE; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; TRANSCRIPTOMICS; TUMOR; TUMOR BIOLOGY; TUMOR CLASSIFICATION;

ADRENAL GLAND NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84858709007     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-012-9195-x     Document Type: Review

References (47)

1. Eisenhofer, G., et al., Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer, 2004. 11(4): p. 897-911. (Pubitemid 40065561)
2. Dahia, P.L., et al., Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res, 2005. 65(21): p. 9651-8. (Pubitemid 41541440)
3. Huynh, T.T., et al., Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Ann N Y Acad Sci, 2006. 1073: p. 241-52.
4. Burnichon, N., et al., Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet, 2011. 20(20): p. 3974-85.
5. Lopez-Jimenez, E., et al., Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol, 2010. 24(12): p. 2382-91.
6. Waldmann, J., et al., Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer, 2010. 17(3): p. 743-56.
7. Brouwers, F.M., et al., Gene expression profiling of benign and malignant pheochromocytoma. Ann N YAcad Sci, 2006. 1073: p. 541-56. (Pubitemid 44912049)
8. Thouennon, E., et al., Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab, 2007. 92(12): p. 4865-72. (Pubitemid 350223470)
9. Dahia, P.L., et al., A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet, 2005. 1(1): p. 72-80.
10. Chi, J.T., et al., Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med, 2006. 3(3): p. e47.
11. Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003. 3(10): p. 721-32. (Pubitemid 37328811)
12. Tian, H., S.L. McKnight, and D.W. Russell, Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev, 1997. 11(1): p. 72-82. (Pubitemid 27043825)
13. Wang, G.L., et al., Hypoxia-inducible factor 1 is a basic-helixloop- helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 1995. 92(12): p. 5510-4.
14. Bruick, R.K. and S.L. McKnight, A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001. 294(5545): p. 1337-40. (Pubitemid 33063099)
15. Epstein,A.C., et al., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 2001. 107(1): p. 43-54 (Pubitemid 32972036)
16. Hewitson, K.S., et al., The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans, 2003. 31(Pt 3): p. 510-5. (Pubitemid 36752676)
17. Favier, J., et al., The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One, 2009. 4(9): p. e7094.
18. Gottlieb, E. and I.P. Tomlinson, Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer, 2005. 5 (11): p. 857-66. (Pubitemid 41746030)
19. Astuti, D., et al., Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet, 2001. 69(1): p. 49-54. (Pubitemid 32614017)
20. Bayley, J.P., et al., SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol, 2010. 11 (4): p. 366-72.
21. Baysal, B.E., et al., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000. 287(5454): p. 848-51. (Pubitemid 30084326)
22. Burnichon, N., et al., SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet, 2010. 19(15): p. 3011-20.
23. Hao, H.X., et al., SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 2009. 325(5944): p. 1139-42.
24. Niemann, S. and U. Muller, Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet, 2000. 26(3): p. 268-70.
25. Selak, M.A., et al., Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 2005. 7(1): p. 77-85. (Pubitemid 40126384)
26. Guzy, R.D., et al., Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxiainducible factor activation and tumorigenesis. Mol Cell Biol, 2008. 28(2): p. 718-31.
27. Lando, D., et al., FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev, 2002. 16(12): p. 1466-71. (Pubitemid 34686328)
28. Mahon, P.C., K. Hirota, and G.L. Semenza, FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev, 2001. 15(20): p. 2675-86. (Pubitemid 32988878)
29. Lisy, K. and D.J. Peet, Turn me on: regulating HIF transcriptional activity. Cell Death Differ, 2008. 15(4): p. 642-9. (Pubitemid 351405067)
30. Cervera, A.M., et al., Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer, 2009. 8: p. 89.
31. Agger, K., et al., The emerging functions of histone demethylases. Curr Opin Genet Dev, 2008. 18(2): p. 159-68. (Pubitemid 351749815)
32. Lin, T.Y., et al., Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16 (INK4a) signaling axis. Oncogene, 2011.
33. Sola, S., et al., p53 interaction with JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS One, 2011. 6(3): p. e18421.
34. Qin, Y., et al., Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet, 2010. 42(3): p. 229-33.
35. Segouffin-Cariou, C. and M. Billaud, Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem, 2000. 275(5): p. 3568-76. (Pubitemid 30083066)
36. Johannessen, C.M., et al., The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A, 2005. 102 (24): p. 8573-8. (Pubitemid 40862777)
37. Yao, L., et al., Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA, 2010. 304(23): p. 2611-9.
38. Zhu, J., J. Blenis, and J. Yuan, Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A, 2008. 105(18): p. 6584-9. (Pubitemid 351754550)
39. Jimenez, R.H., et al., Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR). PLoS One, 2010. 5(2): p. e9084.
40. Huang, S.C., et al., Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res, 2000. 60(22): p. 6223-6.
41. Huang, S.C., et al., Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab, 2003. 88(1): p. 459-63. (Pubitemid 36115202)
42. Comino-Mendez, I., et al., Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet, 2011. 43(7): p. 663-7.
43. Zhang, X., et al., Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res, 2010. 70(6): p. 2350-8.
44. Astuti, D., et al., Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer, 2005. 92(8): p. 1574-80. (Pubitemid 40705027)
45. Pantoja, C., et al., Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res, 2005. 65(1): p. 26-33. (Pubitemid 40070792)
46. Zhang, X., et al., A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab, 2003. 88(11): p. 5119-26. (Pubitemid 37452705)
47. Zhao, J., et al., Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab, 2005. 90(4): p. 2179-86. (Pubitemid 40586259)